ClinicalTrials.gg
CompletedNCT04578353Updated Nov 1, 2023

Effect of Enhanced Sweat Rate on the Safety and Edema Status of Chronic Edematous Patients

An interventional study of The AquaPass System in Chronic Heart Failure, sponsored by AquaPass Medical Ltd.. Completed at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by AquaPass Medical Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2020, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Edema with a site in Israel — 1 open to participants now, 1 under way, none of them phase 3. Edema · Israel.

Enrollment
6th of 11
25 · median 25
Started
2020
the only one that year
No phase
7 of 13
none open now
Registered
10th of 13
by date
Lead sponsor
2 of 13
AquaPass Medical Ltd.

Among the 13 studies in Edema with a site in Israel, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 7 with no phase, and was the 10th registered.

Edema

568 studies on the registry are indexed under Edema; 97 are open to participants now.

Browse Edema studies →

Open to participants now

1 of the 13 studies in Edema with a site in Israel is open now. Recruiting first, the newest first:

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Edema with a site in Israel, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate safety and performance of AquaPass System for enhancing fluid transfer through the skin, by increased sweat rate, in edematous patients.

Read the detailed description

This is a prospective, single-center, open label single arm study, conducted in two phases: up to 6 healthy subjects (Phase 1) and up to 16 chronic heart failure (CHF) patients (Phase 2).

After being informed about the study, requirements and potential risks, consenting patients will be enrolled and undergo 3 procedures (each procedure up to 3 (±1) hours operation), with 4-10 days between each procedure.

All patients will be followed up for 7 (±2) days from final procedure.

03

Conditions studied

  • Chronic Heart Failure

Browse trials for

Keywords

  • CHF
  • Edema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1: Healthy subjects:

  1. Age ≥ 18
  2. Subject has been informed on the nature of the study and has provided
  3. Subject is capable of meeting study requirements

Phase 2: CHF Patients:

  1. Age ≥ 18 and diagnosed with CHF
  2. Subject has 2 or more score for pitting edema
  3. Subject is taking diuretic medications at home
  4. Subject has been informed on the nature of the study and has provided informed consent
  5. Subject is capable of meeting study requirements

Exclusion criteria

Exclusion Criteria:

Phase 1: Healthy subjects:

  1. Subject is enrolled to another clinical investigation that might interfere with this study
  2. Subject is pregnant or planning to become pregnant within the study period, or lactating mothers
  3. Subject has no known sensitivity to Neoprene

Phase 2: CHF Patients:

  1. Subject is enrolled to another clinical investigation that might interfere with this study
  2. Subject is admitted to the hospital for acute decompensated or acute heart failure
  3. Subject has any known lower body skin problems (open wounds, ulcers)
  4. \<15 ml/min/m2
  5. Subject with severe peripheral arterial disease
  6. Subject is pregnant or planning to become pregnant within the study period, or lactating mothers
  7. Subject has known sensitivity to Neoprene
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    AquaPass System

    Participants will undergo 3 procedures (each procedure up to 3 (±1) hours operation) using the AquaPass System, with 4-10 days between each procedure.

    Device: The AquaPass System

Interventions

  • DeviceThe AquaPass System

    The AquaPass device is a capsule that creates relatively homogenous temperature around the patients' lower body, while controlling and maintaining at a low percentage the relative humidity within the capsule thus enabling controlled environment that enhances sweat rate.

06

What researchers measure

Primary outcomes

  1. Safety Events

    Device related SAE

    Time frame: 30 days

  2. System Activation

    Ability to activate the AquaPass System and control skin temperature to levels between 33°C and 38°C

    Time frame: During procedure

  3. Treatment Toleration

    Subjects can tolerate at least 2 hours of treatment

    Time frame: During procedure

Other outcomes

  1. Skin Changes

    Signs of burns grade 1 or more

    Time frame: Before and and immediately after procedure

  2. CBC

    Change in Complete Blood Count

    Time frame: Before and and immediately after procedure

  3. NT-proBNP (phase 2 only)

    Change in N-terminal prohormone of brain natriuretic peptide levels

    Time frame: Before and and immediately after procedure

  4. Serum creatinine, BUN and Sodium

    Change in serum creatinine, blood urea nitrogen (BUN) and sodium levels

    Time frame: Before and and immediately after procedure

  5. Urinary sodium concentration

    Change in urinary sodium concentration

    Time frame: Before and and immediately after procedure

  6. Dyspnea

    Change in dyspnea score

    Time frame: Before and and immediately after procedure

  7. Pitting edema

    Change in pitting edema score

    Time frame: Before and and immediately after procedure

  8. JVD

    Change in jugular venous distention (JVD) score

    Time frame: Before and and immediately after procedure

  9. Weight

    Changes in weight

    Time frame: During and and immediately after procedure

07

Study locations

1 site
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
08

References and documents

Publications

  • Aronson D, Nitzan Y, Petcherski S, Bravo E, Habib M, Burkhoff D, Abraham WT. Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure. Circ Heart Fail. 2023 Jan;16(1):e009787. doi: 10.1161/CIRCHEARTFAILURE.122.009787. Epub 2022 Nov 2. PubMed 36321445 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Feb 2022, 24 months.

Of 168 interventional studies with no phase under Edema, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 8, 2020
StartActual
Jan 28, 2020
Primary completionActual
Feb 12, 2022
CompletionActual
Jun 12, 2022
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578353
Lead sponsor
AquaPass Medical Ltd.
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Jan 28, 2020
Primary completion
Feb 12, 2022
Completion
Jun 12, 2022
Last update
Nov 1, 2023

Study contacts

Doron Aronson, Professor
principal investigator · (Director, Inpatient Cardiology Unit (Rambam Health Care Campus)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion